Why did CVS Health (CVS) stock move recently?

On 9/1/2026, CVS Health moved +3.9% — CVS shares rose on bullish commentary from Jefferies analyst Brian Tanquilut, who named the stock a top pick in large-cap healthcare services with a $120 price target, citing strong multi-year EPS visibility (at least $8.44 for 2027), expected share buybacks, and Aetna margin recovery. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is CVS Health (CVS) overvalued or fairly valued?

MarketChacha shows CVS Health's valuation in context — a trailing P/E of about 42.5, a forward P/E of about 11.4, a price-to-book of about 1.6 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does CVS Health's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.25×) from reported figures — education, not a rating.

What is CVS Health's revenue?

CVS Health reported revenue of $402.1B for FY2025, with net profit of $1.8B, per official filings.

What is the share price of CVS Health (CVS)?

CVS Health last traded at $96.99 (-0.2% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

CVS Health

CVS · NYSE · Healthcare · United States

Snapshot

TickerCVS

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees219,000

HeadquartersWoonsocket, United States

Websitewww.cvshealth.com

Filings tracked16

About CVS Health

CVS Health Corporation provides health solutions in the United States. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental, and behavioral health plans; medical management capabilities; Medicare Advantage and Medicare Supplement plans; prescription drug plans (PDPs); and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail-order pharmacy, clinical services, disease management, medical spend management services, and pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, CMS, plans offered on public health insurance exchanges, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.

Who owns it

Insiders0.1%
Institutions90.9%
Public & other9.1%

2,653 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.63%
Vanguard Capital Management LLC6.51%
Capital World Investors5.86%
State Street Corporation4.71%
Dodge & Cox Inc.3.91%
Wellington Management Group, LLP2.64%
Geode Capital Management, LLC2.34%
FMR, LLC2.26%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 2.4% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion2.25×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend2.3% → 0.4%

Margin has held broadly steady over the period — stable profitability.

Return on equity2.4%

Latest ROE of 2.4% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 6% · PAT -54%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $107.0B · EPS 1.29

Est. earnings growth +18.7%

Next fiscal year

Rev $429.5B · EPS 8.51

Est. earnings growth +7.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$402.1B

Net margin

0.4%

ROE

2.4%

Revenue CAGR (2y)

+6.0%

Profit CAGR (2y)

-54.0%

EPS (FY2025)

1.39

Net profit (FY2025)

$1.8B

Ask MarketChacha about CVS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 1, 2026
CVS shares rose on bullish commentary from Jefferies analyst Brian Tanquilut, who named the stock a top pick in large-cap healthcare services with a $120 price target, citing strong multi-year EPS visibility (at least $8.44 for 2027), expected share buybacks, and Aetna margin recovery.
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about CVS

Why did CVS Health drop ~6% after a big Q2 beat AND raised guidance?c/usmarkets · 8/5/2026▲ 0

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$402.1B	$1.8B	1.39	0.4%	2.4%
FY2024	$372.8B	$4.6B	3.66	1.2%	6.1%
FY2023	$357.8B	$8.3B	6.47	2.3%	10.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$106.1B	$3.0B	2.31	2.8%
2026Q1	$100.4B	$2.9B	2.30	2.9%
2025Q3	$102.9B	$-4.0B	-3.13	-3.9%
2025Q2	$98.9B	$1.0B	0.80	1.0%
2025Q1	$94.6B	$1.8B	1.41	1.9%
2024Q3	$95.4B	$87.0M	0.07	0.1%
2024Q2	$91.2B	$1.8B	1.41	1.9%
2024Q1	$88.4B	$1.1B	0.88	1.3%
2023Q3	$89.8B	$2.3B	1.75	2.5%
2023Q2	$88.9B	$1.9B	1.48	2.1%
2023Q1	$85.3B	$2.1B	1.65	2.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Executive/director change, Shareholder vote results
SEC5/18/2026material
8-K — Results of operations, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Executive/director change
SEC3/19/2026material
8-K — Results of operations, Exhibits
SEC2/10/2026material
10-K filing
SEC2/10/2026

2025

8-K — Reg FD disclosure, Exhibits
SEC12/9/2025material
8-K — Other events, Exhibits
SEC11/20/2025material
8-K — Results of operations, Exhibits
SEC10/29/2025material
10-Q filing
SEC10/29/2025
8-K — Other events, Exhibits
SEC9/22/2025material
8-K — Other events, Exhibits
SEC8/15/2025material
8-K — Results of operations, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.